GSK Return on Investment 2010-2022 | GSK
Current and historical return on investment (ROI) values for GSK (GSK) over the last 10 years.
| GSK ROI - Return on Investment Historical Data |
| Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
| 2022-12-31 |
$7.96B |
$33.56B |
16.91% |
| 2022-09-30 |
$7.70B |
$33.02B |
14.51% |
| 2022-06-30 |
$8.97B |
$52.01B |
15.08% |
| 2022-03-31 |
$9.95B |
$69.58B |
16.28% |
| 2021-12-31 |
$8.53B |
$57.64B |
14.47% |
| 2021-09-30 |
$8.83B |
$58.58B |
15.03% |
| 2021-06-30 |
$8.55B |
$58.74B |
14.68% |
| 2021-03-31 |
$9.75B |
$60.76B |
16.86% |
| 2020-12-31 |
$9.99B |
$56.80B |
17.54% |
| 2020-09-30 |
$10.99B |
$56.79B |
19.56% |
| 2020-06-30 |
$11.24B |
$56.91B |
20.36% |
| 2020-03-31 |
$9.61B |
$57.44B |
19.44% |
| 2019-12-31 |
$8.89B |
$53.56B |
20.31% |
| 2019-09-30 |
$7.78B |
$52.89B |
20.29% |
| 2019-06-30 |
$7.63B |
$33.79B |
22.15% |
| 2019-03-31 |
$6.78B |
$34.80B |
19.16% |
| 2018-12-31 |
$7.32B |
$31.96B |
22.31% |
| 2018-09-30 |
$6.66B |
$37.18B |
21.80% |
| 2018-06-30 |
$6.63B |
$37.58B |
24.09% |
| 2018-03-31 |
$5.54B |
$24.50B |
23.63% |
| 2017-12-31 |
$5.27B |
$22.88B |
22.35% |
| 2017-09-30 |
$5.30B |
$25.04B |
21.63% |
| 2017-06-30 |
$4.72B |
$21.33B |
19.19% |
| 2017-03-31 |
$4.53B |
$25.01B |
17.29% |
| 2016-12-31 |
$3.44B |
$26.60B |
12.31% |
| 2016-09-30 |
$16.06B |
$25.48B |
52.59% |
| 2016-06-30 |
$15.61B |
$27.73B |
46.41% |
| 2016-03-31 |
$16.25B |
$31.94B |
44.67% |
| 2015-12-31 |
$15.85B |
$37.01B |
41.19% |
| 2015-09-30 |
$2.43B |
$37.89B |
6.44% |
| 2015-06-30 |
$2.36B |
$38.67B |
6.47% |
| 2015-03-31 |
$3.69B |
$40.37B |
10.33% |
| 2014-12-31 |
$4.85B |
$34.24B |
13.84% |
| 2014-09-30 |
$8.58B |
$32.37B |
24.09% |
| 2014-06-30 |
$9.94B |
$35.92B |
27.43% |
| 2014-03-31 |
$10.34B |
$37.76B |
28.49% |
| 2013-12-31 |
$10.71B |
$36.41B |
29.32% |
| 2013-09-30 |
$10.61B |
$34.81B |
29.53% |
| 2013-06-30 |
$10.75B |
$36.21B |
30.48% |
| 2013-03-31 |
$11.21B |
$38.71B |
32.33% |
| 2012-12-31 |
$12.04B |
$33.95B |
35.99% |
| 2012-09-30 |
$12.20B |
$32.16B |
36.52% |
| 2012-06-30 |
$12.46B |
$33.84B |
36.21% |
| 2012-03-31 |
$12.62B |
$33.88B |
35.45% |
| 2011-12-31 |
$12.37B |
$33.74B |
33.42% |
| 2011-09-30 |
$8.38B |
$36.17B |
22.00% |
| 2011-06-30 |
$8.30B |
$38.62B |
21.34% |
| 2011-03-31 |
$4.31B |
$39.57B |
11.24% |
| 2010-12-31 |
$4.63B |
$37.97B |
11.91% |
| 2010-09-30 |
$8.98B |
$39.46B |
22.97% |
| 2010-06-30 |
$9.34B |
$36.39B |
23.84% |
| 2010-03-31 |
$14.03B |
$41.61B |
36.80% |
| 2009-12-31 |
$13.35B |
$38.82B |
37.01% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$75.923B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
